<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306618</url>
  </required_header>
  <id_info>
    <org_study_id>ME-CLN-005</org_study_id>
    <nct_id>NCT00306618</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma</brief_title>
  <official_title>A Single-Center, Open-Label, Phase II, Safety, Pharmacokinetic and Efficacy of Panzem Nanocrystal Colloidal Dispersion Administered Orally to Patients With Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CASI Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CASI Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well
      as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal
      Colloidal Dispersion (NCD) administered in patients with recurrent glioblastoma multiforme
      (GBM)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 month progression free survival and median overall survival</measure>
    <time_frame>time of progression; survival</time_frame>
  </primary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Recurrent Glioblastoma Multiforme</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panzem Nanocrystal Colloidal Dispersion</intervention_name>
    <description>Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing</description>
    <other_name>2-methoxyestradiol</other_name>
    <other_name>2ME2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of a 1st or 2nd recurrent/progressive primary WHO
             grade IV malignant glioma (glioblastoma multiforme or gliosarcoma).

          -  18 years or older

          -  An interval of at least 2 weeks between prior surgical resection or any major surgery
             or 4 weeks between prior radiotherapy or chemotherapy (except nitrosoureas which
             require 6 weeks)

          -  Karnofsky performance score equal to or greater than 70%

          -  Hematocrit greater than 29%, absolute neutrophil count greater than 1,500 cells/micro
             liters, platelets greater than 100,000 cells/ micro liters

          -  Serum creatinine less than 1.5 X upper limit of normal (ULN), serum SGOT less than 2.5
             X ULN; and bilirubin less than 1.5 times ULN

          -  Signed informed consent form and authorization for use and disclosure of protected
             health information approved by the IRB prior to patient entry

          -  Agree to use effective contraceptive methods

        Exclusion Criteria:

          -  Current, active systemic bleeding or excessive risk of bleeding

          -  Be pregnant or lactating; not employing effective birth control

          -  Concurrent severe and/or uncontrolled medical disease

          -  Impairment of gastrointestinal (GI) function/disease

          -  Requirement for therapy with coumadin (warfarin sodium)

          -  Patient is less than 5 years free of another primary malignancy

          -  Patients unwilling to or unable to comply with the protocol

          -  Grade 2 or greater peripheral sensory neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A. Reardon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Brain Center at Duke, Duke University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Brain Tumor Center, Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2006</study_first_submitted>
  <study_first_submitted_qc>March 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2006</study_first_posted>
  <last_update_submitted>December 9, 2008</last_update_submitted>
  <last_update_submitted_qc>December 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>EntreMed, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-methoxyestradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

